COVID-19

Nanox Files 2022 Annual Report on Form 20-F

NEVE ILAN, Israel, May 01, 2023 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical…

1 year ago

Financial Results and Business Update Conference Call to be Held May 2023 in Conjunction with 20-F Filing

MIAMI and BARRANQUILLA, Colombia, May 01, 2023 (GLOBE NEWSWIRE) -- Procaps Group, S.A. (NASDAQ: PROC) (“Procaps” or the “Company”), a…

1 year ago

Akari Therapeutics Reports Full-Year 2022 Financial Results and Highlights

Development of lead asset nomacopan, a novel dual-mechanism inhibitor of complement C5 and leukotriene B4 (LTB4), is focused on two…

1 year ago

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

ERAS-801 has demonstrated broad preclinical activity against oncogenic EGFR variants and wildtype alterations Initial THUNDERBBOLT-1 Phase 1 data in patients…

1 year ago

iCAD to Report First Quarter 2023 Financial Results on May 15, 2023

NASHUA, N.H., May 01, 2023 (GLOBE NEWSWIRE) -- iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader providing innovative cancer…

1 year ago

Bioxytran Interview at the Emerging Growth Conference

Wednesday, May 3, 2023 12:35 pm –1:05 pm ESTMedical/Scientific Community Reaction to Peer Reviewed ArticleBOSTON, MASSACHUSETTS, May 01, 2023 (GLOBE…

1 year ago

Cognition Therapeutics Appoints John Doyle to the Role of Chief Financial Officer

PURCHASE, N.Y. , May 01, 2023 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), today announced the appointment of John…

1 year ago

Marker Therapeutics Announces Comprehensive Non-Dilutive Agreement With CellReady™

Structured To Extend Marker’s Financial Runway Through Year-End 2025 Marker Announces Leadership Transition & Provides Update on Operational Strategy HOUSTON,…

1 year ago